572 related articles for article (PubMed ID: 26037791)
21. Paget's disease of the bone: a report of three cases.
Bhatt K; Balakrishnan C; Mangat G; Bajan K; Ashavaid T; Joshi VR
J Assoc Physicians India; 2006 Jul; 54():571-4. PubMed ID: 17089908
[TBL] [Abstract][Full Text] [Related]
22. Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement.
Peris P; Alvarez L; Vidal S; Kasper D; Leeming DJ; Monegal A; Angeles Martínez M; Pons F; Guañabens N
Calcif Tissue Int; 2006 Jul; 79(1):22-6. PubMed ID: 16868670
[TBL] [Abstract][Full Text] [Related]
23. [Is beta 2-microglobulin a marker of bone remodeling in Paget's disease of bone?].
Wilczek H
Cas Lek Cesk; 1997 Dec; 136(23):730-2. PubMed ID: 9476376
[TBL] [Abstract][Full Text] [Related]
24. Zoledronic acid for Paget's disease of bone.
Maricic M
Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
[TBL] [Abstract][Full Text] [Related]
25. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
26. Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.
Polyzos SA; Anastasilakis AD; Anagnostis P; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
Endokrynol Pol; 2012; 63(4):312-5. PubMed ID: 22933168
[TBL] [Abstract][Full Text] [Related]
27. The use of zoledronic acid for Paget's disease of bone.
Maricic M
Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of circulating type I procollagen propeptides in patients with Paget's disease of bone.
Bonnin MR; Moragues C; Nolla JM; Lirón FJ; Roig-Escofet D; Navarro MA
Clin Chem Lab Med; 1998 Jan; 36(1):53-5. PubMed ID: 9594087
[TBL] [Abstract][Full Text] [Related]
29. Quantitative bone scintigraphy in the management of monostotic Paget's disease of bone.
Patel S; Pearson D; Hosking DJ
Arthritis Rheum; 1995 Oct; 38(10):1506-12. PubMed ID: 7575701
[TBL] [Abstract][Full Text] [Related]
30. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
[TBL] [Abstract][Full Text] [Related]
31. Tartrate-resistant acid phosphatase 5b, but not periostin, is useful for assessing Paget's disease of bone.
Guañabens N; Filella X; Florez H; Ruiz-Gaspá S; Conesa A; Peris P; Monegal A; Torres F
Bone; 2019 Jul; 124():132-136. PubMed ID: 31051316
[TBL] [Abstract][Full Text] [Related]
32. [Therapy of Paget's disease].
Kurth AA
Orthopade; 2007 Feb; 36(2):118, 120-3. PubMed ID: 17252256
[TBL] [Abstract][Full Text] [Related]
33. Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.
Cremers SC; Eekhoff ME; Den Hartigh J; Hamdy NA; Vermeij P; Papapoulos SE
J Bone Miner Res; 2003 May; 18(5):868-75. PubMed ID: 12733726
[TBL] [Abstract][Full Text] [Related]
34. Pain in Paget's disease: a retrospective study of treatment efficacy.
Zati A; Colori BC; Bonfiglioli Stagni S; Mignani A
Neuro Endocrinol Lett; 2011; 32(2):127-32. PubMed ID: 21552192
[TBL] [Abstract][Full Text] [Related]
35. Persistent effect of zoledronic acid in Paget's disease.
Tziomalos K; Florentin M; Krikis N; Perifanis V; Karagiannis A; Harsoulis F
Clin Exp Rheumatol; 2007; 25(3):464-6. PubMed ID: 17631747
[TBL] [Abstract][Full Text] [Related]
36. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.
Avramidis A; Polyzos SA; Moralidis E; Arsos G; Efstathiadou Z; Karakatsanis K; Grollios G; Kita M
J Bone Miner Metab; 2008; 26(6):635-41. PubMed ID: 18979164
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone.
Langston AL; Campbell MK; Fraser WD; MacLennan GS; Selby PL; Ralston SH;
J Bone Miner Res; 2010 Jan; 25(1):20-31. PubMed ID: 19580457
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis and management of Paget's disease of bone.
Ralston SH; Langston AL; Reid IR
Lancet; 2008 Jul; 372(9633):155-163. PubMed ID: 18620951
[TBL] [Abstract][Full Text] [Related]
39. Management of Paget's disease of bone.
Langston AL; Ralston SH
Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
[TBL] [Abstract][Full Text] [Related]
40. Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate.
Montagnani A; Gonnelli S; Cepollaro C; Campagna MS; Franci MB; Pacini S; Gennari C
Bone; 2003 Jan; 32(1):15-9. PubMed ID: 12584031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
